• The prevalence of gout is increasing: the coming epidemic

    The prevalence of gout is increasing, despite good treatment options available. Under diagnosis, late diagnosis, undertreatment and discontinuation of treatment contribute to the rising incidence. These data were presented during an Outcome Science Session at the EULAR Annual Congress 2016 in London.

  • Stay connected with EMEUNET

    The Emerging EUlar NETwork (EMEUNET) is a network of young clinicians and researchers in Europe with the aim to improve education in rheumatology.

  • New Psoriatic Arthritis comorbidity index

    A newly developed method of evaluating the impact of different comorbidities in patients with psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death.

  • Non-radiographic and radiographic axSpA treatment

    Most patients with non-radiographic axia Spondyloarthritis (SpA) will progress to active SpA, particularly those with elevated C-reactive protein levels.

  • Golimumab: High persistence in clinical trials and real life settings

    Compared to other biologics, golimumab showed superior persistence rates across different indications and patient groups.

  • Depressive symptoms and juvenile inflammatory arthritis

    One in seven adolescents with juvenile inflammatory arthritis (JIA) experience significant depressive symptoms at diagnosis. Depressive symptoms associate with worse disease and pain at diagnosis with disability over the next three years. These data were presented during a PReS Session at the EULAR Annual Congress 2016 in London.

  • Obesity and smoking lower treatment success in early rheumatoid arthritis

    The likelihood of achieving sustained remission in early rheumatoid arthritis (ERA) is significantly lower in patients who smoke and who are obese. Moreover, these potential modifiable lifestyle factors have a high prevalence in patients with ERA.

  • Axial spondyloarthritis and response on therapy: The earlier the better

    Patients with axial spondyloarthritis who respond early on therapy, show a better persistence long term. Physician's treatment expectations do often not mirror those of the patients.

  • Lupus doubles the risk on cervical neoplasia

    The risk on pre-malignant cervical changes is doubled in women with Systemic Lupus Erythematosus (SLE) compared to the general female population. The highest risks are found in women with SLE who are treated with immunosuppressant drugs. These findings stress the importance for women with SLE to attend cervical screening.

  • Can Biomarkers already guide treatment decisions?

    A post-hoc analysis of a trial in RA patients shows that biomarkers may help to identify patients at risk for progression and thus enable individualised treatment decisions.

  • Patient selection essential for success of viscosupplementation

    Being overweight and radiologic severity of knee osteoarthritis were associated with a lack of response to viscosupplementation in a post hoc analysis of a multicenter, double blind trial.

  • 85 |
  • 86 |
  • 87 |
  • 88 |
  • 89 |
  • 90 |